Key result
Exercise significantly amplified flecainide-induced ventricular conduction slowing, increasing QRS duration from 94 to 116 msec (p<0.001), which did not occur in matched controls.
Why the study?
Does exercise amplify flecainide-induced ventricular conduction slowing in patients treated for cardiac arrhythmias?
Population
19 patients receiving therapeutic doses of flecainide for the treatment of cardiac arrhythmias
Comparison
Treadmill exercise testing by a modified Bruce… vs Age- and disease-matched control group…
Design
Cohort
Authors
Loading...
Exercise may heighten proarrhythmic risk on flecainide; leaves open need for prospective confirmation and activity guidelines.
Observational (n=19)
Does exercise amplify flecainide-induced ventricular conduction slowing in patients treated for cardiac arrhythmias?
p-value: p=<0.001
Exercise significantly amplifies flecainide-induced ventricular conduction slowing, providing a mechanistic explanation for exercise-induced proarrhythmia associated with use-dependent sodium channel blockade.
Ranger et al. (1989) conducted an observational in Cardiac arrhythmias (n=19). Flecainide acetate and exercise vs. Age- and disease-matched control group was evaluated on QRS duration during exercise (p=<0.001). Exercise significantly amplified flecainide-induced ventricular conduction slowing, increasing QRS duration from 94 to 116 msec (p<0.001), which did not occur in matched controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: